Siemens Fonds Invest GmbH Takes $77,000 Position in Embecta Corp. (NASDAQ:EMBC)

Siemens Fonds Invest GmbH bought a new position in shares of Embecta Corp. (NASDAQ:EMBC) during the 4th quarter, HoldingsChannel.com reports. The fund bought 3,707 shares of the company’s stock, valued at approximately $77,000.

Several other institutional investors and hedge funds have also bought and sold shares of EMBC. William Blair Investment Management LLC acquired a new stake in Embecta in the fourth quarter worth $15,270,000. Deerfield Management Company L.P. Series C grew its holdings in Embecta by 19.8% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company’s stock worth $67,537,000 after purchasing an additional 540,192 shares during the period. Raymond James Financial Inc. acquired a new stake in Embecta in the fourth quarter worth $6,598,000. American Century Companies Inc. grew its holdings in Embecta by 8.0% in the fourth quarter. American Century Companies Inc. now owns 3,261,934 shares of the company’s stock worth $67,359,000 after purchasing an additional 242,668 shares during the period. Finally, Brandywine Global Investment Management LLC acquired a new stake in Embecta in the fourth quarter worth $4,043,000. 93.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Mizuho assumed coverage on shares of Embecta in a report on Thursday, April 10th. They issued a “neutral” rating and a $15.00 price target for the company.

Embecta Trading Up 3.1%

Embecta stock opened at $12.02 on Monday. Embecta Corp. has a 1-year low of $10.83 and a 1-year high of $21.48. The firm has a market capitalization of $702.48 million, a price-to-earnings ratio of 12.02, a price-to-earnings-growth ratio of 0.78 and a beta of 1.24. The firm’s fifty day moving average price is $12.31 and its two-hundred day moving average price is $15.69.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, May 9th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The firm had revenue of $259.00 million for the quarter, compared to analyst estimates of $261.77 million. During the same period last year, the firm earned $0.67 earnings per share. The business’s quarterly revenue was down 9.8% compared to the same quarter last year. On average, research analysts forecast that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Wednesday, May 28th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.99%. The ex-dividend date is Wednesday, May 28th. Embecta’s dividend payout ratio (DPR) is 66.67%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.